# Intellia (NTLA) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/NTLA
## Company Profile
- Ticker: NTLA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Gene Therapy
## Stock Data
- Close: 12.02 USD
- Market cap: 1834553497.01 USD
- Last updated: 2026-08-11
## Business Overview
### In Vivo CRISPR Gene Editing
Intellia Therapeutics develops potentially one-time medicines using CRISPR-based gene editing. Its lead programs edit disease-causing genes directly inside the body through systemically delivered therapies.
### Hereditary Angioedema
Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed to reduce kallikrein production for hereditary angioedema. Positive Phase 3 HAELO results support a rolling BLA submission.
### Transthyretin Amyloidosis
Nexiguran ziclumeran, or nex-z, targets the TTR gene to reduce production of transthyretin through a one-time in vivo edit.
### ATTR Cardiomyopathy Program
The Phase 3 MAGNITUDE trial evaluates nex-z in transthyretin amyloidosis with cardiomyopathy, the larger of Intellia's two registrational ATTR indications.
### Hereditary ATTR Polyneuropathy
MAGNITUDE-2 evaluates nex-z in hereditary transthyretin amyloidosis with polyneuropathy, extending the same editing candidate into a neurologic manifestation of the disease.
## Why The Stock Is Moving

As of Aug 11, 2026, NTLA was little changed and closed at $12.02. No new same-company headline was identified in the current news window.

## Future Catalysts

- Completion of the rolling BLA submission for lonvo-z.
- Potential U.S. launch of lonvo-z in the first half of 2027, subject to approval.

## Drug Assets

- lonvoguran ziclumeran

## Recent News
- 2026-08-07 20:01 EST — [Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-220d5920) — Source: Intellia
- 2026-08-06 11:00 EST — [Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-announces-second-quarter-2026-financial-results-and-busine-65d22ddf) — Source: Intellia
- 2026-07-30 12:00 EST — [Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-to-hold-conference-call-on-august-6-to-discuss-second-quar-4c11a227) — Source: Intellia
- 2026-06-13 11:30 EST — [Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-additional-positive-phase-3-results-for-lonvoguran-d89fa3fd) — Source: Intellia
- 2026-06-01 11:30 EST — [Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-to-report-additional-phase-3-haelo-data-for-lonvoguran-ziclumeran-lonvo-z-in-late-breaking-oral-presentation-at-eaaci-2026) — Source: Intellia